Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0GL7H
|
|||
| Former ID |
DIB001392
|
|||
| Drug Name |
Talotrexin
|
|||
| Synonyms |
Talvesta; Talotrexin ammonium; PT-523; PT-633; 10-deaza-PT-523
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 1/2 | [1] | |
| Company |
Hana Biosciences; Dana-Farber Cancer Institute Inc
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C27H27N9O6
|
|||
| Canonical SMILES |
C1=CC=C(C(=C1)C(=O)NCCCC(C(=O)O)NC(=O)C2=CC=C(C=C2)NCC3=CN=C4C(=N3)C(=NC(=N4)N)N)C(=O)O
|
|||
| InChI |
1S/C27H27N9O6/c28-21-20-22(36-27(29)35-21)32-13-16(33-20)12-31-15-9-7-14(8-10-15)23(37)34-19(26(41)42)6-3-11-30-24(38)17-4-1-2-5-18(17)25(39)40/h1-2,4-5,7-10,13,19,31H,3,6,11-12H2,(H,30,38)(H,34,37)(H,39,40)(H,41,42)(H4,28,29,32,35,36)/t19-/m0/s1
|
|||
| InChIKey |
NYQPLPNEESYGNO-IBGZPJMESA-N
|
|||
| CAS Number |
CAS 113857-87-7
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Folate receptor alpha (FOLR1) | Target Info | Antagonist | [2] |
| KEGG Pathway | Endocytosis | |||
| Reactome | COPII (Coat Protein 2) Mediated Vesicle Transport | |||
| Cargo concentration in the ER | ||||
| WikiPathways | Folate Metabolism | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00112060) A Study to Assess the Safety and Preliminary Efficacy of PT-523 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC). U.S. National Institutes of Health. | |||
| REF 2 | Cancer chemotherapy: targeting folic acid synthesis. Cancer Manag Res. 2010; 2: 293-301. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.